Compare Amgen, Inc. (AMGN) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs GE Aerospace — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while GE Aerospace trades at $358.27 (market cap $374.84B). The key difference: GE Aerospace is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | GE | |
|---|---|---|
Market Cap | $196.12B | $374.84B |
Sector | Health | Industrials |
52-Week High | $388.16 | $378.68 |
52-Week Low | $271.18 | $255.42 |
Enterprise Value | $241.41B | $384.14B |
Dividend Yield | 2.77% | 0.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GE Aerospace (GE) trades at $359.27, up 0.06% on the day, with strong technical momentum indicated by bullish moving averages and RSI near neutral. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.86 surpassing the $1.60 estimate. Revenue grew to $45.86B in 2025, while net income reached $8.70B, reflecting robust profitability with a net margin of 18.98%. Recent news highlights defense contract wins and commercial engine demand, supporting positive sentiment.
Outlook remains favorable given earnings beats and aerospace sector strength, but high valuation multiples (P/E 44.63) and debt levels pose risks. Analyst consensus is bullish with a $399.43 price target, suggesting ~11% upside. Key risks include execution challenges and macroeconomic pressures on aviation demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
